Theriva Biologics, Inc.TOVXNYSE
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank56
Year-over-Year Change
Year-over-year free cash flow growth rate
Percentile
P56
Within normal range
vs 2Y Ago
0.4x
Contraction
Streak
3 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 8.25% |
| Q2 2025 | 0.59% |
| Q1 2025 | -1.39% |
| Q4 2024 | -19.88% |
| Q3 2024 | -13.32% |
| Q2 2024 | 29.26% |
| Q1 2024 | 26.01% |
| Q4 2023 | -114.05% |
| Q3 2023 | 20.99% |
| Q2 2023 | 30.56% |
| Q1 2023 | -2.91% |
| Q4 2022 | -22.21% |
| Q3 2022 | -2.22% |
| Q2 2022 | 10.85% |
| Q1 2022 | -1.91% |
| Q4 2021 | -123.10% |
| Q3 2021 | 16.95% |
| Q2 2021 | 22.32% |
| Q1 2021 | -6.53% |
| Q4 2020 | -52.73% |
| Q3 2020 | -1.38% |
| Q2 2020 | 59.15% |
| Q1 2020 | -37.59% |
| Q4 2019 | -17.73% |
| Q3 2019 | -2.68% |
| Q2 2019 | 29.40% |
| Q1 2019 | -28.12% |
| Q4 2018 | 8.47% |
| Q3 2018 | 16.39% |
| Q2 2018 | 29.13% |
| Q1 2018 | -54.49% |
| Q4 2017 | 16.67% |
| Q3 2017 | 17.74% |
| Q2 2017 | 4.64% |
| Q1 2017 | 44.03% |
| Q4 2016 | -75.23% |
| Q3 2016 | -4.71% |
| Q2 2016 | -2.50% |
| Q1 2016 | 48.08% |
| Q4 2015 | 29.43% |